市場調査レポート

商品コード

1773201

動物用医薬品調合の世界市場の評価：製品別、投与経路別、剤形別、地域別、機会、予測（2018年～2032年）

Animal Drug Compounding Market Assessment, By Product, By Animal Type, By Route of Administration, By Dosage Form, By Region, Opportunities and Forecast, 2018-2032F

出版日: 2025年07月21日
発行: Markets & Data
ページ情報: 英文 245 Pages
納期: 3～5営業日

カスタマイズ可能

価格

PDF & Excel Printable (Single User License)

USD 4,800 721,872円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 6,000 902,340円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,500 1,278,315円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=150.39円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の動物用医薬品調合の市場規模は、2024年の19億8,000万米ドルから2032年に36億4,000万米ドルに達すると予測され、予測期間の2025年～2032年にCAGRで7.88%の成長が見込まれます。市場は、錠剤を風味のある液体に変換したり、異なる種やサイズに合わせて投与量を調整したり、外用ジェルや咀嚼剤を作ったりする調合薬の需要が高まっているため、急成長を示しています。

動物用医薬品調合市場は、動物医療提供者やペットの飼い主が、動物の個々のニーズに対応するカスタマイズされた医薬品を求めていることから、着実に注目を集めています。資格を持つ薬剤師は、獣医師とともに、標準的な商業製品にはないカスタムメイドの剤形、強度、薬物の組み合わせを開発できる調合手順を通じて医薬品を調合します。この市場は、標準的な医薬品が不適切であったり入手できなくなったりして、動物の治療がうまくいかない場合に不可欠なソリューションとなります。コンパニオンアニマルと家畜の動物医療サービスにおいて、よりよい治療結果を得ると同時に、動物が薬を服用しやすくし、健康を守るために、調合薬の使用が増加しています。ペットが標準的な薬に含まれる不活性成分に対してアレルギー反応を示す場合や、体重に応じた投与量を個別に測定する必要がある場合、またはペットが服用を改善するために風味をつけた薬を必要とする場合、このような不可欠な薬の投与が必要となります。ペットのウェルネスに関する支出は、ペット個体数の世界的な増加とともに増加し続けており、その結果、カスタマイズされた動物用医薬品の需要が増加しています。皮膚科、内分泌科、腫瘍科、神経科、慢性疼痛管理を含む獣医学的治療の複雑化が、個別化された治療ソリューションへのニーズを大幅に高めています。ペットの人間化の動向と世界の調合薬局ネットワークの拡大は、引き続き市場成長を促進します。

例えば2024年9月、WEDGEWOOD PHARMACYは、猫伝染性腹膜炎（FIP）の一次治療と二次治療に用いる新しい治療薬として、調合モルヌピラビルを処方集に導入しました。元々はヒト用の合剤でしたが、猫に合うように特別に風味付けされ、調合されました。WEDGEWOOD PHARMACYは、滲出性、非滲出性、神経性、眼性などのさまざまなFIPのタイプに対応するさまざまな投与オプションを含む猫用モルヌピラビル調合を提供する米国初の動物用医薬品調合薬局です。この調合には、風味付きの懸濁剤とカプセルの剤形があります。

当レポートでは、世界の動物用医薬品調合市場について調査分析し、市場規模と予測、市場力学、主要企業の情勢などを提供しています。

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- 製品別
  - 抗感染剤
  - 抗炎症剤
  - ホルモン、代替品
  - CNS剤
  - その他
- 動物タイプ別
  - コンパニオンアニマル
  - 家畜
- 投与経路別
  - 経口
  - 注射
  - 外用
- 剤形別
  - 懸濁剤
  - 液剤
  - カプセル
- 地域別
  - 北米
  - 欧州
  - アジア太平洋
  - 南米
  - 中東・アフリカ
- 市場シェア分析：企業別（上位5社とその他）（金額）（2024年）
市場マップ分析（2024年）
- 製品別
- 動物タイプ別
- 投与経路別
- 剤形別
- 地域別

第6章北米の動物用医薬品調合市場の見通し（2018年～2032年）

市場規模の分析と予測
- 金額
市場シェアの分析と予測
- シェア：国別
  - 米国
  - カナダ
  - メキシコ
各国の市場の評価
- 米国の動物用医薬品調合市場の見通し（2018年～2032年）
  - 市場規模の分析と予測
  - 市場シェアの分析と予測
- カナダ
- メキシコ

第7章欧州の動物用医薬品調合市場の見通し（2018年～2032年）

ドイツ
フランス
イタリア
英国
ロシア
オランダ
スペイン
トルコ
ポーランド

第8章アジア太平洋の動物用医薬品調合市場の見通し（2018年～2032年）

インド
中国
日本
オーストラリア
ベトナム
韓国
インドネシア
フィリピン

第9章南米の動物用医薬品調合市場の見通し（2018年～2032年）

ブラジル
アルゼンチン

第10章中東・アフリカの動物用医薬品調合市場の見通し（2018年～2032年）

サウジアラビア
アラブ首長国連邦
南アフリカ

第11章需給の分析

第12章バリューチェーン分析

第13章ポーターのファイブフォース分析

第14章 PESTLE分析

第15章価格分析

第16章市場力学

市場促進要因
市場の課題

第17章市場動向と発展

技術の概要
近年の発売と承認

第18章規制枠組みとイノベーション

第19章ケーススタディ

第20章競合情勢

マーケットリーダー上位5社の競合マトリクス
上位5社のSWOT分析
主要企業上位10社の情勢
- Partners Group
- Vimian Group AB
- Akina Animal Health
- Davis Islands Pharmacy and Compounding Lab
- Custom Med Compounding Pharmacy
- Central Compounding Center South
- Wellness Pharmacy of Cary
- Kubat HealthCare
- Medisca Inc.
- Chiron Pharmaceuticals Private Limited

第21章戦略的提言

第22章調査会社について・免責事項

図表

List of Tables

Table 1. Competition Matrix of Top 5 Market Leaders
Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1. Global Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 2. Global Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 3. Global Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 4. Global Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 5. Global Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 6. Global Animal Drug Compounding Market Share (%), By Region, 2018-2032F
Figure 7. North America Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 8. North America Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 9. North America Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 10. North America Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 11. North America Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 12. North America Animal Drug Compounding Market Share (%), By Country, 2018-2032F
Figure 13. United States Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 14. United States Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 15. United States Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 16. United States Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 17. United States Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 18. Canada Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 19. Canada Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 20. Canada Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 21. Canada Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 22. Canada Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 23. Mexico Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 24. Mexico Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 25. Mexico Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 26. Mexico Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 27. Mexico Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 28. Europe Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 29. Europe Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 30. Europe Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 31. Europe Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 32. Europe Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 33. Europe Animal Drug Compounding Market Share (%), By Country, 2018-2032F
Figure 34. Germany Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 35. Germany Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 36. Germany Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 37. Germany Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 38. Germany Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 39. France Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 40. France Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 41. France Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 42. France Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 43. France Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 44. Italy Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 45. Italy Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 46. Italy Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 47. Italy Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 48. Italy Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 49. United Kingdom Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 50. United Kingdom Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 51. United Kingdom Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 52. United Kingdom Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 53. United Kingdom Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 54. Russia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 55. Russia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 56. Russia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 57. Russia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 58. Russia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 59. Netherlands Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 60. Netherlands Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 61. Netherlands Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 62. Netherlands Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 63. Netherlands Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 64. Spain Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 65. Spain Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 66. Spain Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 67. Spain Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 68. Spain Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 69. Turkey Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 70. Turkey Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 71. Turkey Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 72. Turkey Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 73. Turkey Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 74. Poland Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 75. Poland Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 76. Poland Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 77. Poland Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 78. Poland Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 79. South America Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 80. South America Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 81. South America Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 82. South America Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 83. South America Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 84. South America Animal Drug Compounding Market Share (%), By Country, 2018-2032F
Figure 85. Brazil Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 86. Brazil Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 87. Brazil Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 88. Brazil Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 89. Brazil Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 90. Argentina Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 91. Argentina Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 92. Argentina Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 93. Argentina Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 94. Argentina Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 95. Asia-Pacific Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 96. Asia-Pacific Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 97. Asia-Pacific Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 98. Asia-Pacific Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 99. Asia-Pacific Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 100. Asia-Pacific Animal Drug Compounding Market Share (%), By Country, 2018-2032F
Figure 101. India Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 102. India Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 103. India Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 104. India Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 105. India Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 106. China Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 107. China Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 108. China Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 109. China Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 110. China Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 111. Japan Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 112. Japan Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 113. Japan Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 114. Japan Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 115. Japan Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 116. Australia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 117. Australia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 118. Australia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 119. Australia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 120. Australia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 121. Vietnam Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 122. Vietnam Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 123. Vietnam Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 124. Vietnam Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 125. Vietnam Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 126. South Korea Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 127. South Korea Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 128. South Korea Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 129. South Korea Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 130. South Korea Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 131. Indonesia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 132. Indonesia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 133. Indonesia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 134. Indonesia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 135. Indonesia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 136. Philippines Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 137. Philippines Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 138. Philippines Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 139. Philippines Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 140. Philippines Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 141. Middle East & Africa Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 142. Middle East & Africa Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 143. Middle East & Africa Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 144. Middle East & Africa Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 145. Middle East & Africa Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 146. Middle East & Africa Animal Drug Compounding Market Share (%), By Country, 2018-2032F
Figure 147. Saudi Arabia Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 148. Saudi Arabia Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 149. Saudi Arabia Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 150. Saudi Arabia Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 151. Saudi Arabia Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 152. UAE Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 153. UAE Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 154. UAE Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 155. UAE Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 156. UAE Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 157. South Africa Animal Drug Compounding Market, By Value, In USD Billion, 2018-2032F
Figure 158. South Africa Animal Drug Compounding Market Share (%), By Product, 2018-2032F
Figure 159. South Africa Animal Drug Compounding Market Share (%), By Animal Type, 2018-2032F
Figure 160. South Africa Animal Drug Compounding Market Share (%), By Route of Administration, 2018-2032F
Figure 161. South Africa Animal Drug Compounding Market Share (%), By Dosage Form, 2018-2032F
Figure 162. By Product Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 163. By Animal Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 165. By Dosage Form Map-Market Size (USD Billion) & Growth Rate (%), 2024
Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Product Code: MX13696

Global animal drug compounding market is projected to witness a CAGR of 7.88% during the forecast period 2025-2032, growing from USD 1.98 billion in 2024 to USD 3.64 billion in 2032. The animal drug compounding market is experiencing rapid growth due to the rising demand for compounded medications, which include converting tablets into flavored liquids, adjusting dosages for different species or sizes, or creating topical gels and chews.

The animal drug compounding market is steadily gaining prominence as veterinary healthcare providers and pet owners seek customized pharmaceutical products that address the individual needs of their animals. Licensed pharmacists, along with veterinarians, prepare medications through compounding procedures, which enable them to develop custom dosage forms, strengths, and drug combinations that standard commercial products do not offer. The market serves as an essential solution for animal care situations where standard medications fail because they are either inappropriate or no longer available. The use of compounded medications has grown in both companion and livestock animal health services to achieve better treatment results while making it easier for animals to take their medications and protect their well-being. The administration of these essential drugs becomes necessary when pets display allergic reactions to inactive components in standard medications, or when weight-based dosing requires individualized measurement, or when pets need flavored medication to improve administration. Pet wellness expenditures continue to rise alongside the global growth of the pet population, leading to increased demand for customized veterinary medications. The expanding complexities of veterinary treatments that involve dermatology, endocrinology, oncology, neurology, and chronic pain management have significantly increased the need for personalized therapeutic solutions. The pet humanization trend and the expansion of the global compounding pharmacy network continue to fuel market growth.

For instance, in September 2024, WEDGEWOOD PHARMACY introduced compounded molnupiravir into its formulary as a new therapy for first- and second-line treatment of Feline Infectious Peritonitis (FIP). The original human medical compound was specially flavored and prepared to make it suitable for cats. WEDGEWOOD PHARMACY stands as the inaugural U.S. veterinary compounding pharmacy to offer cat-friendly molnupiravir formulations, which include different dosage options that address various FIP types, including Effusive, Non-effusive, Neurological, and Ocular. The preparations come in both flavored suspension and capsule forms.

Rising Pet Ownership Trend and Humanization of Pets Boost Market Demand

Pet ownership trends, along with the rising humanization of pets, are the primary forces driving the expansion of the animal drug compounding market. The growing number of pet owners who treat their animals as family members drives a substantial market need for healthcare products that offer personalization. The current pet owner population prioritizes individualized treatment approaches through dose modifications, flavor customization, and diverse administration options, which enhance therapeutic outcomes. The developing emotional connection between people and their pets now requires veterinary care services to match human medical standards. Compounded medications offer adaptable solutions when standard pharmaceutical products fail to meet patient needs or when products become unavailable or discontinued. For example, compounding enables the development of customized liquid medications and topical gels which match the individual characteristics of feline patients and canine patients according to their size, breed and health conditions. Customized pharmaceutical solutions enhance patient comfort and treatment effectiveness while simplifying medication administration for patients with persistent and complex health conditions. The rising number of pets and the demand for tailored treatment solutions have made compounding pharmacies essential in veterinary medical practice. The expanding pet care culture drives market growth, emphasizing the need for individualized pharmaceutical solutions to meet the demands of modern pet owners.

For instance, according to the American Pet Products Association's (APPA) survey report, as of March 2025, 94 million U.S. households now own at least one pet, up from 82 million in 2023. The rising population of pet ownership increases the demand for animal drug compounding to enhance the medication solutions for their pets and provide them with a higher quality of life.

Advancement in Compounding Technology Fuels Market Growth

Advancements in compounding technology significantly fuel the growth of the animal drug compounding market by enhancing the precision of medication preparation while increasing efficiency and safety. The use of automated equipment in modern compounding pharmacies, including precision mixers and capsule fillers, together with electronic balances, leads to improved consistency and accuracy in custom drug formulations. Technology minimizes human errors and ensures accurate dosing, while also enhancing processing speed, making compounded medications more dependable and easier for veterinarians and pet owners to obtain. The pharmaceutical industry has developed new excipients and delivery systems that include transdermal gels, along with flavored suspensions and medicated treats, which now offer multiple administration methods while enhancing palatability for companion animals. Pharmacies optimize their operations and maintain proper safety standards through advanced software solutions, which enable inventory tracking, prescription management, and regulatory compliance. The installation of sterile compounding facilities, along with quality assurance protocols, ensures that veterinary and human health standards are consistently met for all medications. Veterinary professionals show increased confidence in compounded medications due to these technological advancements, which enhance both production speed and quality. Technological advancements drive the global growth of animal drug compounding services while improving their reliability.

For instance, in January 2025, Covetrus Inc. launched a cloud-based compounding prescription platform called the Covetrus Platform, which comprises an integrated solution set designed to meet the needs of contemporary veterinary operations. The Covetrus Platform collaborates with the expanding VetSuite network to deliver comprehensive veterinary clinic capabilities nationwide.

Oral Route of Administration Segment Holds the Largest Market Share

The oral route of administration holds the largest market share in the animal drug compounding market due to its universal approval and species versatility, as well as its user-friendly nature. Veterinarians, along with pet owners, often select flavored liquids, chewable tablets, capsules, and pastes as their preferred oral medications because these options simplify the administration of drugs to companion animals, including dogs and cats. Compounding pharmacies create customized medications that improve taste to increase animal compliance for those animals that resist medication intake. Chronic conditions need this method because it provides ongoing daily medication for arthritis infections and endocrine disorders. The flexibility of oral formulations stems from their ability to customize doses according to weight, species, and individual health requirements, resulting in cost savings. Through oral delivery, pharmacists can access numerous active pharmaceutical ingredients (APIs) to develop individualized treatment options that are more effective than commercial drugs or when commercial products are not available. The advancement of flavor masking techniques, combined with improvements in formulation stability, has enhanced both the performance and storage duration of compounded oral medications. The increasing demand for customized pet medications, together with easy administration techniques, sustains oral administration as the leading method in animal drug compounding markets.

For instance, in October 2023, Evonik Industries AG launched EUDRACAP, a ready-to-use oral capsule filler designed for use in preclinical trials. This technical-grade capsule is suitable for passing through the gastrointestinal tract of preclinical animal models. The company also introduced this on the clinical and commercial stages using the EUDRACAP platform.

North America Dominates Animal Drug Compounding Market Size

North America dominates the animal drug compounding market due to its advanced veterinary healthcare facilities, high pet ownership rates, and supportive regulations. The United States holds a significant portion of the market due to its growing demand for personalized pet medications that cater to specific health conditions, dosage requirements, and species-specific formulations. Veterinary professionals, along with pet owners, turn to compounded medications as their first choice when commercial drugs become unavailable, unsuitable, or discontinued. The regional market receives additional strength from Wedgewood Pharmacy and other leading compounding pharmacies. The regional market is bolstered by Wedgewood Pharmacy and other leading compounding pharmacies, which offer a range of dosage forms, flavors, and delivery methods for both companion animals and livestock. The region maintains established distribution networks, along with professional veterinary associations, which continually invest in veterinary compounding techniques and training. Regulatory bodies such as the U.S. FDA develop operational rules for pharmacies while promoting safety standards for compounded medications. The growing awareness of pet health needs, combined with the rise of chronic disease management and pet humanization trends, is driving market demand for customized medical solutions. The combination of various market elements establishes North America as the primary force in the worldwide animal drug compounding industry.

For instance, in December 2024, Grey Wolf Animal Health Corp., a Toronto-based company, completed the acquisition of Compounding Pharmacy of Manitoba. Grey Wolf enhances its ability to provide custom veterinary drugs through the growth of its pharmacy business unit and expanded capacity to deliver veterinary and human compounding services. Through its acquisition of Trutina and Compounding Pharmacy of Manitoba, Grey Wolf expands its customer base while increasing access to specialized animal medications and driving market growth.

Impact of U.S. Tariffs on Animal Drug Compounding Market

The implementation of U.S. tariffs on pharmaceutical ingredients and raw materials imported from overseas has a significant impact on the animal drug compounding industry. Several compounded medications rely on receiving their active pharmaceutical ingredients (APIs) and excipients from suppliers in China and India. Tariffs increase the expense of imported goods, which raises production costs for veterinary compounding pharmacies. Higher production costs result in elevated prices for compounded medications, which pet owners and veterinary facilities must pay. Smaller veterinary compounding operations encounter difficulties when increasing prices due to their reliance on tight profit margins, which sustain their individualized animal medication offerings. Supply chain restrictions that block access to ingredients lead to medication delays, which in turn postpone necessary medical treatments. The transition toward domestic sourcing by providers results in higher expenses or reduced product availability. The implementation of tariffs generates financial strain on compounding pharmacies while endangering both the affordability and availability of animal medical care.

Key Players Landscape and Outlook

The competitive landscape operates through innovation, acquisitions, and service expansion. Custom formulation delivery, compounding technology, quality assurance, and training investment drive company growth. Strategic partnerships, combined with geographical expansion, enable companies to achieve a broader market reach. Their competitive advantage is strengthened through species-specific solutions and delivery forms that meet compliance requirements and stringent regulatory standards. The market outlook appears positive, as personalized veterinary care shows increasing demand, while R&D investments are expected to continue driving both market growth and product differentiation.

In May 2024, Mixlab, Inc. acquired NexGen Animal Health, enabling the expansion of its advanced compounding pharmacy operations from companion animal services to include extensive animal health services. Mixlab aims to utilize its technology platform to enhance pharmacy services for large animal practitioners and owners, while improving production efficiency and supporting ongoing development.

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Animal Drug Compounding Market Outlook, 2018-2032F

5.1. Market Size Analysis & Forecast
- 5.1.1. By Value
5.2. Market Share Analysis & Forecast
- 5.2.1. By Product
  - 5.2.1.1. Anti-infective Agents
  - 5.2.1.2. Anti-inflammatory Agents
  - 5.2.1.3. Hormones and Substitutes
  - 5.2.1.4. CNS Agents
  - 5.2.1.5. Others
- 5.2.2. By Animal Type
  - 5.2.2.1. Companion Animals
    - 5.2.2.1.1. Dogs
    - 5.2.2.1.2. Cats
    - 5.2.2.1.3. Horses
    - 5.2.2.1.4. Others
  - 5.2.2.2. Livestock Animals
- 5.2.3. By Route of Administration
  - 5.2.3.1. Oral
  - 5.2.3.2. Injectable
  - 5.2.3.3. Topical
- 5.2.4. By Dosage Form
  - 5.2.4.1. Suspensions
  - 5.2.4.2. Solutions
  - 5.2.4.3. Capsules
- 5.2.5. By Region
  - 5.2.5.1. North America
  - 5.2.5.2. Europe
  - 5.2.5.3. Asia-Pacific
  - 5.2.5.4. South America
  - 5.2.5.5. Middle East and Africa
- 5.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
5.3. Market Map Analysis, 2024
- 5.3.1. By Product
- 5.3.2. By Animal Type
- 5.3.3. By Route of Administration
- 5.3.4. By Dosage Form
- 5.3.5. By Region

6. North America Animal Drug Compounding Market Outlook, 2018-2032F

6.1. Market Size Analysis & Forecast
- 6.1.1. By Value
6.2. Market Share Analysis & Forecast
- 6.2.2. By Country Share
  - 6.2.2.1. United States
  - 6.2.2.2. Canada
  - 6.2.2.3. Mexico
6.3. Country Market Assessment
- 6.3.1. United States Animal Drug Compounding Market Outlook, 2018-2032F*
  - 6.3.1.1. Market Size Analysis & Forecast
    - 6.3.1.1.1. By Value
  - 6.3.1.2. Market Share Analysis & Forecast
    - 6.3.1.2.1. By Product
      - 6.3.1.2.1.1. Anti-infective Agents
      - 6.3.1.2.1.2. Anti-inflammatory Agents
      - 6.3.1.2.1.3. Hormones and Substitutes
      - 6.3.1.2.1.4. CNS Agents
      - 6.3.1.2.1.5. Others
    - 6.3.1.2.2. By Animal Type
      - 6.3.1.2.2.1. Companion Animals
      - 6.3.1.2.2.1.1. Dogs
      - 6.3.1.2.2.1.2. Cats
      - 6.3.1.2.2.1.3. Horses
      - 6.3.1.2.2.1.4. Others
      - 6.3.1.2.2.2. Livestock Animals
    - 6.3.1.2.3. By Route of Administration
      - 6.3.1.2.3.1. Oral
      - 6.3.1.2.3.2. Injectable
      - 6.3.1.2.3.3. Topical
    - 6.3.1.2.4. By Dosage Form
      - 6.3.1.2.4.1. Suspensions
      - 6.3.1.2.4.2. Solutions
      - 6.3.1.2.4.3. Capsules
- 6.3.2. Canada
- 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Animal Drug Compounding Market Outlook, 2018-2032F

7.1. Germany
7.2. France
7.3. Italy
7.4. United Kingdom
7.5. Russia
7.6. Netherlands
7.7. Spain
7.8. Turkey
7.9. Poland

8. Asia-Pacific Animal Drug Compounding Market Outlook, 2018-2032F

8.1. India
8.2. China
8.3. Japan
8.4. Australia
8.5. Vietnam
8.6. South Korea
8.7. Indonesia
8.8. Philippines

9. South America Animal Drug Compounding Market Outlook, 2018-2032F

9.1. Brazil
9.2. Argentina

10. Middle East and Africa Animal Drug Compounding Market Outlook, 2018-2032F

10.1. Saudi Arabia
10.2. UAE
10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

16.1. Market Drivers
16.2. Market Challenges

17. Market Trends and Developments

17.1. Technology Overview
17.2. Recent Launches and Approvals

18. Regulatory Framework and Innovation

19. Case Studies

20. Competitive Landscape

20.1. Competition Matrix of Top 5 Market Leaders
20.2. SWOT Analysis for Top 5 Players
20.3. Key Players Landscape for Top 10 Market Players
- 20.3.1. Partners Group
  - 20.3.1.1. Company Details
  - 20.3.1.2. Key Management Personnel
  - 20.3.1.3. Products and Services
  - 20.3.1.4. Financials (As Reported)
  - 20.3.1.5. Key Market Focus and Geographical Presence
  - 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
- 20.3.2. Vimian Group AB
- 20.3.3. Akina Animal Health
- 20.3.4. Davis Islands Pharmacy and Compounding Lab
- 20.3.5. Custom Med Compounding Pharmacy
- 20.3.6. Central Compounding Center South
- 20.3.7. Wellness Pharmacy of Cary
- 20.3.8. Kubat HealthCare
- 20.3.9. Medisca Inc.
- 20.3.10. Chiron Pharmaceuticals Private Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

動物用医薬品調合の世界市場の評価：製品別、投与経路別、剤形別、地域別、機会、予測（2018年～2032年）

Animal Drug Compounding Market Assessment, By Product, By Animal Type, By Route of Administration, By Dosage Form, By Region, Opportunities and Forecast, 2018-2032F

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国関税の影響

第4章 エグゼクティブサマリー

第5章 世界の動物用医薬品調合市場の見通し（2018年～2032年）

第6章 北米の動物用医薬品調合市場の見通し（2018年～2032年）

第7章 欧州の動物用医薬品調合市場の見通し（2018年～2032年）

第8章 アジア太平洋の動物用医薬品調合市場の見通し（2018年～2032年）

第9章 南米の動物用医薬品調合市場の見通し（2018年～2032年）

第10章 中東・アフリカの動物用医薬品調合市場の見通し（2018年～2032年）

第11章 需給の分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析